Cargando…

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

OBJECTIVES: To document improvement in quality of life in patients with Hepatitis-C related cirrhosis after successful eradication of the virus. METHODS: In this observational cohort study conducted at Fatima Memorial Hospital from September 2015 to July 2017, patients with HCV were assessed for imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Bushra, Raja, Ikram Ul Haq, Choudhry, Asad, Nawaz, Arif Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121959/ https://www.ncbi.nlm.nih.gov/pubmed/35634624 http://dx.doi.org/10.12669/pjms.38.4.4537

Ejemplares similares

Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)
por: Azam, Zahid, et al.
Publicado: (2017)

Hepatitis C eradication with sofosbuvir leads to significant metabolic changes
por: Morales, Amilcar L, et al.
Publicado: (2016)

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
por: Al Moussawi, Hassan, et al.
Publicado: (2018)

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
por: Tarao, Kazuo, et al.
Publicado: (2021)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens
por: Chen, Jianhong, et al.
Publicado: (2017)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
por: Babatin, Mohammed A., et al.
Publicado: (2019)

Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report
por: Fraga, Montserrat, et al.
Publicado: (2019)

An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir
por: Soliman, Megan Sue, et al.
Publicado: (2018)

Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients
por: He, Xiaoping, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals
por: Townshend-Bulson, Lisa, et al.
Publicado: (2021)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
por: Pellicelli, Adriano, et al.
Publicado: (2020)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature
por: Haga, Yuki, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation
por: Reddy, Suresh, et al.
Publicado: (2018)

The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
por: Sacramento, Carolina Q., et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Antiviral therapy of HCV in the cirrhotic and transplant candidate
por: Herrine, Steven K., et al.
Publicado: (2006)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt
por: Nagaty, Ahmed, et al.
Publicado: (2017)

Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents
por: Glombicki, Stephen E, et al.
Publicado: (2021)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Synergized immunization programming: Pakistan’s road to polio eradication
por: Haq, Zaeem ul, et al.
Publicado: (2021)

Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals
por: Armandi, Angelo, et al.
Publicado: (2022)

Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
por: Sacramento, Carolina Q., et al.
Publicado: (2017)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
por: Lynch, Erica Nicola, et al.
Publicado: (2023)

Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism
por: Sparvoli, Jucéli Márcia Hendges, et al.
Publicado: (2022)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
por: Leleu, H, et al.
Publicado: (2015)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a83imkn3u1ro5qc2484nmjt4k6